Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8105418rdf:typepubmed:Citationlld:pubmed
pubmed-article:8105418lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:8105418lifeskim:mentionsumls-concept:C0205474lld:lifeskim
pubmed-article:8105418lifeskim:mentionsumls-concept:C0026447lld:lifeskim
pubmed-article:8105418lifeskim:mentionsumls-concept:C0000097lld:lifeskim
pubmed-article:8105418lifeskim:mentionsumls-concept:C0543482lld:lifeskim
pubmed-article:8105418lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:8105418pubmed:issue3lld:pubmed
pubmed-article:8105418pubmed:dateCreated1993-11-23lld:pubmed
pubmed-article:8105418pubmed:abstractTextThe behavioural, biochemical and morphological effects of a chronic administration of low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were studied in the common marmoset. Monkeys received the toxin (1 mg/kg i.p.) twice a week for four months. Group A monkeys were studied one week after the last injection of MPTP; group B monkeys were studied eight months after the last toxic injection. The monkey behaviour was observed throughout the experiment; the biochemical and morphological correlates were studied post mortem in the neostriatum and in the substantia nigra, respectively. Data collected from MPTP-treated marmosets were compared to those obtained from sham-injected control monkeys. The results can be summarized as follows. (1) In all MPTP-treated marmosets a progressive Parkinsonism occurred. In group B monkeys, a gradual behavioural recovery was observed after MPTP was discontinued. (2) Biochemical analysis of group A marmosets showed a depletion of dopamine, of 3,4-hydroxyphenylacetic acid and of homovanillic acid, and no variations in dopamine turnover in the neostriatum of MPTP-treated marmosets. In group B, biochemical analysis showed no differences between controls and MPTP-treated animals. (3) Morphological analysis showed that the density of midbrain dopaminergic neurons located in the substantia nigra was unchanged in group A monkeys, but was reduced by 6.8% in MPTP-treated monkeys of group B. The measurement of cross-sectional area showed that midbrain dopaminergic neurons were swollen in MPTP-treated monkeys of group A, with a 11.0% increase of cell size as compared to controls. In group A the nuclei were also swollen, being 304.8% larger in MPTP-treated monkeys, with a nucleus-to-cytoplasm ratio of 65.9% (as compared to 34.0% of controls). In group B monkeys cell size was increased by 18.4% in MPTP-treated marmosets, but the nuclei were of comparable size. The present data show that a chronic administration of low doses of MPTP brings about biochemical and morphological abnormalities. The first occur acutely in terminals and are reverted early after discontinuance of exposure to the toxin; the latter occur in dopaminergic perikarya, last longer than biochemical abnormalities and, at variance with them, increase in severity after MPTP is discontinued. Morphological abnormalities include early events, such as a transient swelling of nuclei or a long-lasting swelling of neurons, and late events, such as a decrease in the number of tyrosine hydroxylase-positive perikarya.(ABSTRACT TRUNCATED AT 400 WORDS)lld:pubmed
pubmed-article:8105418pubmed:languageenglld:pubmed
pubmed-article:8105418pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8105418pubmed:citationSubsetIMlld:pubmed
pubmed-article:8105418pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8105418pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8105418pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8105418pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8105418pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8105418pubmed:statusMEDLINElld:pubmed
pubmed-article:8105418pubmed:monthAuglld:pubmed
pubmed-article:8105418pubmed:issn0306-4522lld:pubmed
pubmed-article:8105418pubmed:authorpubmed-author:AlbaneseAAlld:pubmed
pubmed-article:8105418pubmed:authorpubmed-author:TonaliPPlld:pubmed
pubmed-article:8105418pubmed:authorpubmed-author:PiccardiM PMPlld:pubmed
pubmed-article:8105418pubmed:authorpubmed-author:ColosimoCClld:pubmed
pubmed-article:8105418pubmed:authorpubmed-author:GranataRRlld:pubmed
pubmed-article:8105418pubmed:authorpubmed-author:GregoriBBlld:pubmed
pubmed-article:8105418pubmed:issnTypePrintlld:pubmed
pubmed-article:8105418pubmed:volume55lld:pubmed
pubmed-article:8105418pubmed:ownerNLMlld:pubmed
pubmed-article:8105418pubmed:authorsCompleteYlld:pubmed
pubmed-article:8105418pubmed:pagination823-32lld:pubmed
pubmed-article:8105418pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:meshHeadingpubmed-meshheading:8105418-...lld:pubmed
pubmed-article:8105418pubmed:year1993lld:pubmed
pubmed-article:8105418pubmed:articleTitleChronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates.lld:pubmed
pubmed-article:8105418pubmed:affiliationIstituto di Neurologia, Università Cattolica del Sacro Cuore, Roma, Italy.lld:pubmed
pubmed-article:8105418pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8105418pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8105418lld:pubmed